R406

Item no.	HY-12067-10mM
Manufacturer	MedChem Express
CASRN	841290-81-1
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	96.70
Citations	[1]Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008.\|[2]Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8. ACS Infect Dis. 2021 Mar 12;7(3):661-671.\|Ann Transl Med. 2019 Dec;7(23):758.\|Arthritis Rheumatol. 2018 Sep;70(9):1419-1428. \|Atherosclerosis. 2019 Oct;289:132-142.\|bioRxiv. 2022 Dec 21, 519945.\|bioRxiv. 2024 Apr 9.\|Blood Adv. 2024 Nov 12;8(21):5653-5662.\|BMC Cardiovasc Disord. 2024 Jul 12;24(1):354.\|Cell Commun Signal. 2024 Apr 2;22(1):210.\|Cell Rep Med. 2025 Jan 16:101922.\|Cell Rep. 2023 Mar 20;42(3):112275.\|Cell. 2018 Oct 4;175(2):442-457.e23.\|Exp Hematol Oncol. 2022 Nov 8;11(1):88.\|Front Pharmacol. 2022 May 5;13:885053.\|iScience. 2024 June 28.\|iScience. 2024 Mar 25.\|J Biol Chem. 2018 Apr 27;293(17):6410-6433.\|J Neuroinflammation. 2024 Dec 3;21(1):318.\|J Pharmacol Sci. 2017 May;134(1):29-36.\|Life Metab. 2025 Jan 29.\|Mol Immunol. 2024 Jul 31:173:88-98.\|Nat Commun. 2022 Apr 19;13(1):2136.\|Nihon University. School of Medicine. 2014 Mar.\|Redox Biol. 3 September 2022, 102461.\|Scand J Immunol. 2024 Apr 26:e13371.\|Theranostics. 2021 May 24;11(15):7308-7321.\|Adv Mater. 2024 Mar 15:e2311283.\|Harvard Medical School LINCS LIBRARY\|iScience. 2024 Jan 8.\|Mater Today Bio. 2024 Mar 22, 101037.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|SSRN. 2023 Jun 29.
Smiles	COC1=CC(NC2=NC(NC3=NC(N4)=C(C=C3)OC(C)(C)C4=O)=C(C=N2)F)=CC(OC)=C1OC.OS(C5=CC=CC=C5)(=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	841290-81-1
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; FLT3; Syk
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	628.63
Product Description	R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation[1]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[2].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO: ≥ 61 mg/mL
Manufacturer - Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12067-10mM-safety-datasheet.pdf